Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 12/20 | 0.63 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.63 |
| ▸ | MMP9 | P14780 | 9/20 | 0.57 |
| ▸ | MMP1 | P03956 | 2/20 | 0.57 |
| ▸ | MMP13 | P45452 | 2/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.57 |
| ▸ | MMP7 | P09237 | 1/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8839630 | 1.00 | MMP2 (0.63) | MMP2ADAMTS5MMP9MMP1MMP13 | |
| SCHEMBL5875639 | 0.88 | MMP2 (0.60) | MMP2ADAMTS5MMP9MMP1MMP13 | |
| SCHEMBL8839754 | 0.88 | MMP2 (0.60) | MMP2ADAMTS5MMP9MMP1MMP13 | |
| SCHEMBL8839423 | 0.86 | MMP2 (0.64) | MMP2ADAMTS5MMP9MMP1MMP13 | |
| SCHEMBL8839436 | 0.86 | MMP2 (0.64) | MMP2ADAMTS5MMP9MMP1MMP13 | |
| SCHEMBL3397101 | 0.86 | TDP1 (0.64) | MMP2MMP9MMP1MMP13MMP3 | |
| SCHEMBL3427026 | 0.86 | TDP1 (0.64) | MMP2MMP9MMP1MMP13MMP3 | |
| SCHEMBL3392197 | 0.86 | TDP1 (0.64) | MMP2MMP9MMP1MMP13MMP3 | |
| SCHEMBL8839281 | 0.85 | MMP2 (0.57) | MMP2ADAMTS5MMP9MMP1MMP13 | |
| SCHEMBL8839291 | 0.85 | MMP2 (0.57) | MMP2ADAMTS5MMP9MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093231-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | TELIK, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-5650428-A | THROMBOXANE A2 ANTAGONISM | NKK CORPORATION (JP) | 1997-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | MTAP, TYMP, PHOSPHO1 | MMP2 4669/4885ADAMTS5 4397/4885MMP9 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.